Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EU Opinion On Moderna’s mRNA-1273 Expected This Week, UK Boosts Vaccine Rollout As Lockdown Imposed

Executive Summary

UK biotech firm Emergex has signed a deal with Brazil’s Biocruz for the development of a T-cell based vaccine, and the Philippines regulator has issued a warning after reports that members of the country’s presidential guard received an unauthorized vaccine produced by China’s Sinopharm.

You may also be interested in...



EU Approval Of Oxford/AstraZeneca COVID-19 Vaccine Expected By End Of January

AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford. 

UK Begins Controversial 12 Week Strategy With AZ and Pfizer Vaccines

Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.

Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP

AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel